AbCellera, based in Arlington, MA, is a biotechnology company at the forefront of developing improved antibody medicines for patients through innovative technologies and strategic partnerships with leading pharmaceutical companies. Specializing in antibody discovery and development, the company focuses on T-cell engagers for cancer and other therapeutic targets, with a dedicated team of scientists, engineers, and business professionals committed to advancing the boundaries of science and technology.
Known for its active participation in scientific conferences and collaborations with industry partners, AbCellera is driving innovation in the field of antibody therapeutics to deliver enhanced therapies to patients. With a strong emphasis on pushing the limits of research and development, the company's internal pipeline of programs aims to break barriers and bring about significant advancements in the healthcare industry.